{
  "docId": "019de075-5375-74ac-b63e-223f7dcbcdee",
  "docSlug": "1e5a737805b52115da5825472ef93325",
  "documentTitle": "Hillstream BioPharma | Investor Presentation Deck | 19 slides",
  "authorId": "hillstream-biopharma",
  "authorName": "Hillstream BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 19,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": "The slide uses a Gantt-style visual for the 'Pre-clinical' stage, though it is not a full timeline.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-5375-74ac-b63e-223f7dcbcdee/5",
  "deckHref": "/decks/019de075-5375-74ac-b63e-223f7dcbcdee",
  "deckJsonHref": "/decks/019de075-5375-74ac-b63e-223f7dcbcdee.json",
  "deckAnchorHref": "/decks/019de075-5375-74ac-b63e-223f7dcbcdee#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.12,
        "y": 0.78
      },
      "kind": "source-note",
      "text": "1PicoKnobs from Minotaur/OmniAb; Bsp - bispecific",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa69dfc0-1aff-4ae2-a8cb-11a899d00b76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.94,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "table",
      "text": "Pipeline table with columns: Modality, Candidate, Target/Mechanism, Pre-clinical, Clinical, Anticipated Milestones",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7dac7241-94c8-4acc-8901-54a85ce39df0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Solid Tumor Pipeline: Validated Targets & Unmet Needs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be6bbc91-4028-4777-b1d6-4c4eddd937d8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "9ce6509b-b099-413f-84d7-e3b1d7972a4c",
      "evidence": "The pipeline table uses horizontal bars to represent the pre-clinical development stage.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [
    {
      "to": 6,
      "from": 5,
      "beatId": "ca6d71f0-73d0-4404-9801-7d1194b80d6b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "Slides 5-6 discuss the unmet needs and market opportunity in HER2/HER3 targeting",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 14,
      "from": 4,
      "beatId": "e53add27-632d-4b4f-baf0-308f53797da9",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 4-14 present the company's solution, including the lead program HSB-3215 and its technical advantages",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "009743bf-d073-473d-9caa-f2a330433b67",
      "evidence": "Slides 5-6 imply that not addressing these unmet needs will result in continued poor outcomes for patients",
      "position": 0,
      "objective": "Highlight the consequences of not addressing the unmet needs in HER2/HER3 targeting",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}